MODERNA COVID VACCINE FUNDING INFUSION
Another $472 Million in Funds from US Government
Potentially Quick Vaccine Development and Delivery
Cambridge, MA based Moderna just announced it has received an additional $472 million in funding from the US government's Biomedical Advanced Research and Development Authority (BARDA). That brings the total from BARDA to support the development of Moderna's novel COVID vaccine to $955 million.
mRNA
Moderna is the first pharma company in the US to begin human trials on a COVID vaccine. Tomorrow, July 27th, a Phase 3 study involving 30,000 participants will get underway with Moderna collaborating with the National Institute of Allergy and Infectious Diseases. Moderna's vaccine candidate uses synthetic messenger RNA (mRNA) to help the body immunize against the virus.
Potential Quick Delivery
Moderna says it can deliver 500,000 doses of the vaccine per year and possibly 1 billion doses per year starting in 2021. Experts say their approach can be developed and manufactured more quickly than traditional vaccines. Britain's AstraZeneca and Pfizer are also getting funding from BARDA to develop COVID vaccines.
 |
| Source: Moderna Cambridge, MA |
Potentially Quick Vaccine Development and Delivery
Cambridge, MA based Moderna just announced it has received an additional $472 million in funding from the US government's Biomedical Advanced Research and Development Authority (BARDA). That brings the total from BARDA to support the development of Moderna's novel COVID vaccine to $955 million.
mRNA
Moderna is the first pharma company in the US to begin human trials on a COVID vaccine. Tomorrow, July 27th, a Phase 3 study involving 30,000 participants will get underway with Moderna collaborating with the National Institute of Allergy and Infectious Diseases. Moderna's vaccine candidate uses synthetic messenger RNA (mRNA) to help the body immunize against the virus.
Potential Quick Delivery
Moderna says it can deliver 500,000 doses of the vaccine per year and possibly 1 billion doses per year starting in 2021. Experts say their approach can be developed and manufactured more quickly than traditional vaccines. Britain's AstraZeneca and Pfizer are also getting funding from BARDA to develop COVID vaccines.
Comments
Post a Comment